Acute lymphoblastic leukaemia develops in both children and adults, with a peak incidence
between 1 year and 4 years. Most acute lymphoblastic leukaemia arises in healthy …

The outcomes of pediatric acute lymphoblastic leukemia (ALL) have improved remarkably
during the last five decades. Such improvements were made possible by the incorporation of …

Acute lymphoblastic leukemia (ALL) is the most common childhood cancer, and despite cure
rates exceeding 90% in children, it remains an important cause of morbidity and mortality in …

Natural killer/T cell lymphoma (NKTCL) is an aggressive and heterogeneous entity of non-
Hodgkin lymphoma, strongly associated with Epstein-Barr virus (EBV) infection. To identify …

Contemporary paediatric clinical trials have improved 5-year event-free survival above 85%
and 5-year overall survival above 90% in B-cell acute lymphoblastic leukaemia (ALL) in …

Most B cell precursor acute lymphoblastic leukemia (BCP ALL) can be classified into known
major genetic subtypes, while a substantial proportion of BCP ALL remains poorly …

We evaluated clinical significance of recently identified subtypes of acute lymphoblastic
leukemia (ALL) in 598 children treated with minimal residual disease (MRD)–directed …

The cure rate of childhood acute lymphoblastic leukemia (ALL) has exceeded 90% in some
contemporary clinical trials. However, the dose intensity of conventional chemotherapy has …

NUT carcinoma (NC) is a rare, aggressive subtype of squamous cell carcinoma defined by
rearrangement of the NUTM1 (aka NUT) gene. NC is driven by NUT‐fusion oncoproteins …

Acute lymphoblastic leukemia (ALL) is a heterogeneous group of hematologic malignancies
characterized by abnormal proliferation of immature lymphoid cells. It is the most commonly …